. Blood transcriptional signature of recombinant human erythropoietin administration and implications for antidoping strategies. Physiol Genomics 48: 202-209, 2016. First published January 12, 2016 doi:10.1152/physiolgenomics.00108.2015.-Recombinant human erythropoietin (rHuEPO) is frequently abused by athletes as a performance-enhancing drug, despite being prohibited by the World AntiDoping Agency. Although the methods to detect blood doping, including rHuEPO injections, have improved in recent years, they remain imperfect. In a proof-of-principle study, we identified, replicated, and validated the whole blood transcriptional signature of rHuEPO in endurance-trained Caucasian males at sea level (n ϭ 18) and Kenyan endurance runners at moderate altitude (n ϭ 20), all of whom received rHuEPO injections for 4 wk. Transcriptional profiling shows that hundreds of transcripts were altered by rHuEPO in both cohorts. The main regulated expression pattern, observed in all participants, was characterized by a "rebound" effect with a profound upregulation during rHuEPO and a subsequent downregulation up to 4 wk postadministration. The functions of the identified genes were mainly related to the functional and structural properties of the red blood cell. Of the genes identified to be differentially expressed during and post-rHuEPO, we further confirmed a whole blood 34-transcript signature that can distinguish between samples collected pre-, during, and post-rHuEPO administration. By providing biomarkers that can reveal rHuEPO use, our findings represent an advance in the development of new methods for the detection of blood doping. blood doping; erythropoiesis, mRNA ERYTHROPOIETIN IS A HORMONE that regulates the production of new red blood cells (erythropoiesis) (18). Administration of recombinant human erythropoietin (rHuEPO) improves sporting performance (10) and hence is frequently subject to abuse by athletes, despite being prohibited by the World Anti-Doping Agency (WADA). The direct detection of rHuEPO doping is challenging because rHuEPO is structurally very similar to endogenous erythropoietin and rapidly disappears from the circulation. The Athlete Biological Passport (ABP) was introduced as a new tool to provide indirect evidence for the use of erythropoiesis-stimulating agents such as rHuEPO by identifying abnormal intraindividual variability in selected blood parameters over time (34). While approaches to detect blood doping, including rHuEPO injections, are improving, the declarations of confessed dopers emphasize the need for further refinement of current detection methods.
erythropoiesis-stimulating agents such as rHuEPO by identifying abnormal intraindividual variability in selected blood parameters over time (34) . While approaches to detect blood doping, including rHuEPO injections, are improving, the declarations of confessed dopers emphasize the need for further refinement of current detection methods.
The typical goal of "omics"-based research is the identification of new and specific molecular biomarkers for the diagnosis, monitoring, and prognosis of diseases. The same approach can be used for monitoring the efficacy of drug therapy (22) . Here, we applied an omics-based approach in human volunteers to generate a transcriptional signature of rHuEPO for antidoping purposes. We first describe the specific alterations of the blood transcriptional profiles induced by rHuEPO administration in two distinct and independent groups. We then validate a whole blood 34-transcript signature using another quantitative gene technology and performed in a subset of fifty selected genes. Finally, we demonstrate the implications of our findings for antidoping strategies. The identification of the blood transcriptional signature of rHuEPO provides the basis for the development of new and improved models to detect blood doping. Our study also provides a broad range of transcriptional biomarkers relevant for understanding the variability in responsiveness to rHuEPO therapy.
METHODS
Experimental design. Eighteen endurance-trained Caucasian males at sea level (SCO; 26.0 Ϯ 4.5 yr, 74.8 Ϯ 7.9 kg, 179.8 Ϯ 5.4 cm) (10) and 20 east African endurance runners from the Kalenjin tribe in Kenya (KEN; 26.4 Ϯ 4.1 yr, 56.6 Ϯ 4.7 kg, 171.8 Ϯ 6.4 cm) at moderate altitude (ϳ2,150 m) participated in the study. All subjects underwent a medical assessment and provided written informed consent to participate. Subjects were requested to maintain their normal training but abstain from official sporting competition for the duration of the research study (16) . This study was approved by the Ethics Committees of the University of Glasgow (Scotland, UK) and Moi University (Kenya) and conformed to the Declaration of Helsinki. The subjects subcutaneously self-injected 50 IU/kg body mass of rHuEPO (NeoRecormon, Roche) every second day for 4 wk (Fig. 1A) . Daily oral iron supplementation (ϳ100 mg of elemental iron, ferrous sulfate tablets, Almus) was given during the 4 wk of rHuEPO administration.
Blood sampling and RNA extraction. After 10 min of rest in the supine position, 3 ml of whole blood was collected into Tempus Blood RNA tubes (Life Technologies) from an antecubital vein in triplicate at baseline, during rHuEPO administration and for 4 wk after rHuEPO administration. The Tempus tubes were vigorously mixed immediately after collection, incubated at room temperature for 3 h and stored between Ϫ20°C and Ϫ80°C before RNA extraction. Eight time points per subjects were selected for gene expression analysis (Fig. 1, A and B) . RNA was extracted using the MagMAX for stabilized blood tubes RNA isolation kit (Life Technologies) or the Tempus Spin RNA isolation kit (Life Technologies). RNA yield was determined using a NanoDrop spectrophotometer (Thermo Fisher Scientific) and the RNA integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent technologies) showing a quality of RNA integrity number of 8.5 Ϯ 0.9 [95% confidence intervals (CI) 8.4 to 8.6 and ranging from 5.0 to 9.8]. RNA was stored at Ϫ80°C until further analysis.
Microarray experiment and data analysis. We selected 18 subjects in each cohort for the microarray experiment. Extracted RNA was prepared with the Illumina TotalPrep RNA Amplification Kit (Life Technologies). The RNA amplification consists of synthesizing cRNA by in vitro transcription from the cDNA produced by reverse transcription from 500 ng of RNA. We then randomly hybridized 750 ng of the purified labeled cRNA samples to the Illumina HumanHT-12 v4.0 Expression BeadChip arrays, which contain Ͼ47,000 probes, following the manufacturer's recommended procedures (Illumina). The Bead arrays were scanned on the Illumina BeadArray Reader, and raw intensity values were saved in Illumina GenomeStudio software. Following the manufacturer's instructions, Illumina GenomeStudio quality control metrics were used to assess the quality of the samples; all samples passed these assessments.
For normalization, Illumina GenomeStudio software was used to subtract background and to perform quantile normalization. Using R software environment (http://www.r-project.org/), we then log2-transformed normalized probe level intensities after adding a small constant to avoid negative values as well as to reduce the influence of probes with low signal intensities close to the background noise. The constant's value was chosen after inspection of scatter plots of the two baseline samples from each individual. To remove the array effect, we fitted a linear model to the each gene's data using array as the predictor, and the coefficients for each array were removed from each value. These normalized data were used for all downstream analyses. Rank Products analysis (4) with a 5% false discovery rate (3) was used to identify the differentially expressed transcripts during and post rHuEPO administration compared with baseline values. An additional 1.5-fold-change threshold was applied for a more stringent analysis. The differences in genes expression between the two cohorts by time-interaction were analyzed with R-package Limma (linear models for microarray) (33) with a 5% false discovery rate (3) . Functional analysis of differentially expressed genes was performed using Ingenuity Pathway Analysis (Ingenuity Systems) with Fisher's exact test to calculate a P value determining the probability that each biological function and/or network assigned to the identified genes was due to chance alone, with a Benjamini-Hochberg correction for multiple testing applied. All microarray data are available in the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-2874.
QuantiGene Plex experiment and data analysis. QuantiGene Plex assay (Affymetrix) was used for further confirmation of the microarray results. The QuantiGene Plex assay combines branched DNA (bDNA) signal amplification and xMAP profiling magnetic beads technologies (Luminex). The bDNA enables target RNA quantification by amplifying the reporter signal rather than target sequences and the xMAP fluorescent microspheres or "beads" are used as a support to capture specific RNA molecules (12) . The MicroArray Quality Control (MAQC) project has demonstrated the good precision and accuracy of the QuantiGene Plex assay (5) . A subset of 50 identified genes was selected for confirmation using QuantiGene Plex. The selection of these 50 genes was based on the following criteria: magnitude of the changes in expression; relative expression above background level; low interindividual responses in gene expression pattern; consistency between the Illumina probes targeting different transcripts for the same gene; biological relevance. We selected 18 and 20 subjects in the SCO and KEN cohorts for the QuantiGene Plex experiment, respectively. Two different RNA inputs of 100 and 200 ng for each sample were hybridized and amplified using the QuantiGene Plex assay and following the manufacturers' recommended procedures (Affymetrix). The fluorescence signal was read on the MAGPIX (Luminex), and median fluorescence intensity values were saved using xPonent software. Data were exported to R software environment where background subtraction, log2 transformation, and normalization to four housekeeping genes (ACTB, ACTR10, MRFAP1, and RAB11A) were performed. These normalized data were used for all downstream analyses. R-package Limma (33) with a 5% false discovery rate (3) was used to confirm expression profiles.
Blood parameters analysis. Hematology analysis including reticulocyte percentage and hematocrit was performed from homogenized whole blood collected in EDTA tubes using fluorescence flow cytometry and hydrodynamic focusing (Sysmex XT-2000i, Sysmex). Reticulocyte percent data were exported to R software environment where log ratio compared with baseline values was calculated. The reticulocyte effect was controlled by regression modelling in the R-package Limma (33) using the regression coefficient as a scaling factor. The curve of the relationship between reticulocyte and genes that remained significantly differentially expressed after we controlled for the effect of reticulocyte was fitted using polynomial local regression (loess).
Prediction using k-nearest neighbor. For class prediction and estimation of the discriminatory performance, we used the k-nearest neighbors method from the R-package "class," with six neighbors. The 34 genes validated by QuantiGene Plex were used for prediction of samples collected pre-, during, and post-rHuEPO administration, as well as for prediction of samples collected at 2 days after the first rHuEPO injection. The prediction model was trained using fivefold cross-validation on 30 randomly selected subjects (training set: SCO n ϭ 14 and KEN n ϭ 16). This model was then used to predict the classification of the samples in the remaining eight subjects (test set: SCO n ϭ 4 and KEN n ϭ 4) and to determine sensitivity, specificity, and 95% CI. List of the 32 and 5 genes differentially and commonly expressed in both groups during and post recombinant human erythropoietin (rHuEPO) administration identified by the microarray experiment (Fig. 1C) .
RESULTS
rHuEPO administration profoundly alters blood transcriptional profiles. To identify changes in the blood transcriptome after rHuEPO administration, we first generated genome-wide whole blood transcriptional profiles from the SCO cohort. The previously published phenotypic results confirmed that rHuEPO administration increased red blood cell mass and improved exercise performance (10) . Transcriptional profiling shows that hundreds of transcripts were altered by rHuEPO administration (Fig. 1C) . Using a combination of changes in expression-level and robust statistical criteria, we identified a 41-transcript signature, distinct from baseline values, at 2 days after the first injection that remained altered throughout rHuEPO administration (Fig. 1, B and C, and Supplementary File Data Set S1).
1 At the same time, a distinct 10-transcript signature was defined by differential expression after rHuEPO administration that remained differentially expressed up to 4 wk postadministration (Fig. 1, B and C, and Supplementary File Data Set S2).
Similar changes in blood transcriptional profiles were observed in all individuals. To replicate our findings, we then applied a similar genome-wide transcriptional approach to the independent KEN cohort, who underwent a similar rHuEPO administration regimen. The initial findings were replicated, and only minimal significant differences were found between the two groups. More precisely, only three transcripts (DARC, JAK3, and CCDC71) were found to be differentially regulated between SCO and KEN.
Of the genes already differentially expressed 2 days after the first injection compared with baseline in the SCO and KEN cohorts, 32 transcripts were commonly regulated, while five transcripts were commonly regulated postadministration in the two groups (Table 1, Fig. 1C , and Supplementary File Data Sets S1-S4). The main regulated expression pattern of the identified signature was characterized by a "rebound" effect with a profound upregulation during rHuEPO and a subsequent downregulation up to 4 wk postadministration. The same transcriptional signature pattern was observed in all participants. CA1 gene was selected to exemplify the signature pattern observed in all 32 transcripts (Fig. 1D and Supplementary File Data Sets S1-S4).
Whole blood transcriptional signature of rHuEPO reflects distinct changes in gene expression and production of new red blood cells. The genes profoundly upregulated during rHuEPO and subsequently downregulated postadministration were mainly related to hematological, hematopoietic, and cardiovascular system development and function ( Fig. 2A) , such as the 1 The online version of this article contains supplemental material. differentiation of the red blood cells (Fig. 2B ) and in agreement with the observed changes in blood parameters (Fig. 2C) .
Validation, using another quantitative gene technology and performed in a subset of 50 selected genes, confirmed the whole blood 34-transcript signature ( Fig. 3 and Supplementary File Data Set S5).
Although reticulocytes have shed their nucleus, they retain quantities of residual nucleic acid material (11) . As such, we tested the hypothesis that the identified whole blood 34-transcript signature may reflect the relative proportion of immature red blood cells (reticulocytes) compared with white blood cells. The rHuEPO-induced changes in expression observed in the identified genes were correlated with the changes in reticulocyte percentage (Supplementary File Data Set S5). Nevertheless, even after we controlled for the effect of reticulocytes, changes in gene expression compared with baseline values still reached significance levels in several genes (Fig. 4 and Supplementary File Data Set S5). In particular, four genes (EPB42, SELENBP1, SLC4A1, and PITHD1) showed that the blood transcriptional signature can be more sensitive than reticulocyte percentage in detecting changes in blood profiles induced by only one rHuEPO injection (Fig. 4 and Supplementary File Data Set S5).
Discriminatory performance and antidoping implications. The k-nearest neighbor prediction model was able to distinguish between samples collected pre-, during, and postrHuEPO administration with overall sensitivity and specificity of 79.4% (95% CI 74.8 -83.9%) and 94.7% (95% CI 92.2-97.3%), respectively (Table 2) . Finally, and most importantly for current antidoping challenges, the k-nearest neighbor prediction gave a sensitivity of 58.6% (95% CI 42.7-74.4%) and a specificity of 97.4% (95% CI 93.8 -100%) for specifically distinguishing samples collected at baseline and at 2 days after only one rHuEPO injection, which would typically remain undetectable by the current tests using standard blood parameters (1).
DISCUSSION AND CONCLUSIONS
rHuEPO is frequently abused by athletes as a performanceenhancing drug, despite being prohibited by WADA. Using transcriptional profiling from whole blood, we provide proof of principle for a new transcriptionally enhanced model for the detection of rHuEPO doping. In this study, we first identified the changes in blood transcriptional profiles in perturbed erythropoiesis via rHuEPO administration in endurance-trained individuals in Scotland. The results were then replicated in KEN, and only minimal significant differences were found with SCO. Some of the only few differences observed between the two groups, such as in DARC and JAK3, may be explained by gene polymorphisms. For instance, polymorphisms in DARC are the basis of the Duffy blood group system, which is associated with resistance to Plasmodium vivax malaria (44) . Using another quantitative gene technology and performed in a subset of 50 selected genes, we then validated the whole blood 34-transcript signature. Finally, we tested the discriminatory performance of this blood transcriptional signature. We anticipate our results to be the starting point for a new transcriptionally enhanced model for the detection of blood doping.
Biological functions of the identified signature. The whole blood transcriptional signature of rHuEPO administration showed biologically coherent changes in gene expression. In particular, the functional and structural components of the red blood cells were dominant in the 34-transcript signature, for example, the heme synthesis (ALAS2, FECH, and SNCA) (28, 30) , the transport of oxygen and carbon dioxide (HBD, BPGM, CA1, and SLC4A1) (13, 14, 24) , the organization and connectivity of the red blood cell membrane (EPB42, TMOD1, GYPE, and RBM38) (15, 17, 29, 36) , the control of reactive oxygen species, which can potentially induce cell apoptosis (BCL2L1 and SELENBP1) (26, 32) , the regulation of the cell cycle, and the differentiation of blood cells during erythropoiesis (FBXO7) (7), the purine metabolism (GMPR and GUK1), as well as genes of unknown function in the red blood cell but Log Ratio(relative to average Baseline) Log Ratio Ret% (relative to average Baseline)
x=y x=0 y=0 Fig. 4 . Relationship between changes in reticulocyte and genes that remained significantly differentially expressed after controlling for the effect of reticulocyte.
which were previously reported to be relevant to the red blood cell biology (TRIM58, CSDA, DCAF12, FAM46C, STRADB, ADIPOR1, PITHD1, and UBXN6) (6, 37, 40, 43) . These findings support the view that the gene set identified here is enriched for genes involved in the biological processes related to the red blood cell, particularly during late-stage erythropoiesis.
From a clinical perspective, rHuEPO and other erythropoiesis stimulating agents are widely used in the treatment of anemia. The introduction of rHuEPO was a paradigm shift in the treatment of patients with anemia due to, for example, chronic kidney disease, as it dramatically reduced the use of blood transfusions and their associated morbidity (20) . However, there is a need to better understand the variability as well as to predict and improve responsiveness to rHuEPO therapy (20) . As such, our data provide a series of candidate biomarkers relevant to investigating the variability in response to rHuEPO treatment.
Detection of early changes in erythropoiesis. In the bone marrow, erythropoietin binds to the erythropoietin receptor and activates the Jak2-STAT5 signaling cascade, which then stimulates the survival, proliferation, and differentiation of red blood cell progenitors (18) without affecting the white blood cells' production (19) . Following the initial development and maturation in the bone marrow, the reticulocytes are then released in the bloodstream before developing into mature red blood cells. Because reticulocytes still retain quantities of residual nucleic acid material (11), the identified whole blood 34-transcript signature may reflect the relative proportion of immature red blood cells (reticulocytes) compared with white blood cells. The correlation between the rHuEPO-induced changes in gene expression with the changes in reticulocyte percentage is in agreement with previously reported correlation between red cell distribution width, which often reflects a higher percentage of reticulocytes, and a cluster of 57 genes that include several genes also identified in the present study, such as EPB42, SLC4A1, ALAS2, TMOD, CSDA, GMPR, and BPGM (41) . Nonetheless, changes in gene expression still reached significance levels in several genes even after we controlled for the effect of reticulocytes.
The observation that the blood transcriptional signature, in particular four genes (EPB42, SELENBP1, SLC4A1, and PITHD1), can be more sensitive than reticulocyte percentage in detecting early changes in erythropoiesis in whole blood is particularly relevant for the challenge that faces current antidoping methods to detect small doses of rHuEPO. Indeed, to minimize the risk of being caught via the ABP, it is well recognized that athletes are now using so-called "microdoses" of rHuEPO that allegedly range from 10 to a maximum of 40 IU/kg body mass. These small or microdoses of rHuEPO aim to increase red blood cell mass while avoiding large fluctuations in ABP blood markers and/or "normalizing" these markers after blood manipulations such as autologous blood transfusion, as well as minimizing the detection window for conventional direct methods (23) . However, the ABP did not detect a single case of rHuEPO when a microdosing strategy was adopted (1). The k-nearest neighbor prediction results for specifically distinguishing samples collected at baseline and at 2 days after only one rHuEPO injection are promising results to detect a small dose of rHuEPO. The k-nearest neighbor classifier is a robust method that has been shown to be very effective in gene expression classification (9) . However, it is essentially a naïve machine learning algorithm that does not take into account when the sample was taken, for example. There thus remains scope for the discriminatory performance to be even further improved by using more sophisticated methods, such as the ABP adaptive Bayesian model (35) , once normal physiological molecular reference profiles are generated.
Study limitations. The fact that the present study was not blinded and did not include a control group may limit the interpretations of the direct applications of the findings. However, participants were able to act as their own controls to an extent, and any placebo effects are unlikely to have yielded the extent of differential expression and the characteristic profiles observed in differentially regulated genes. In addition, based on the recent admissions by confessed dopers, the rHuEPO dose regimen used in this study (i.e., 50 IU/kg body mass every 2 days for 4 wk) does not closely reproduce the strategy of microdoses rHuEPO doping typically currently used by athletes (23) . However, this study was not designed to exactly mimic drug-taking behavior, but, rather, it was designed as a proof of principle of the transcriptomic approach to detection of rHuEPO. Furthermore, as a consequence of the promising results discussed here, we have already designed a randomized, double-blind, placebo-controlled cross-over study involving microdosing (25). The top row represents the observed phases (2A) or time points (2B), and the 1st column represents the k-nearest neighbor predictions. The results in boldface are correctly classified results in percentage. The majority of the misclassifications affecting the sensitivity of the detection of rHuEPO arose at 2 days after only rHuEPO injection (EPO3) and 1 wk after ceasing rHuEPO administration (Post6), when the gene expression is crossing baseline levels due to the "rebound" effect. Implications for antidoping strategies and conclusions. Earlier studies, limited by small number of subjects or animals and using the serial analysis of gene expression method, already reported some modifications of blood gene expression after rHuEPO administration (2, 38, 39) . Here we provide the first complete description of the human blood transcriptional signature of altered erythropoiesis in response to rHuEPO administration. The k-nearest neighbor approach can distinguish between samples collected pre-, during, and post-rHuEPO administration. Moreover, a transcriptionally enhanced model can potentially reduce the logistical challenges and cost incurred in sample collection and analysis. Current antidoping blood samples have important logistic and cost implications since blood samples must be shipped refrigerated (4°C) and analyzed within 48 h of collection (42) , whereas the blood samples, RNA stabilized in Tempus tubes (Life Technologies) of a transcriptionally enhanced model, are easy to handle and stable for 5-7 days at room temperature and for years when kept frozen prior to analysis (8, 21, 27, 31) . However, further validations using rHuEPO doping regimens more similar to what is currently thought to be used, with smaller doses and more sophisticated ABP-like modelling methods as well as the generation of normal physiological reference ranges, are required before the blood transcriptional signature-based approach delivers on its promise to add a new dimension to the current detection methods used by WADA. These promising results might also mean that other banned substances could be detectable with transcriptomic approaches. However, their effectiveness may vary according to the substance considered and the tissue type available.
In summary, our results provide evidence to support a transcriptionally enhanced approach for the detection of blood doping. Our study also provides new insights into a broad range of transcriptional biomarkers relevant for understanding the biological mechanisms involved in erythropoiesis.
